FDA propose drug label changes for use in pregnancy

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2008年 / 1205卷 / 1期
关键词：
Pregnant Woman; Potential Risk; Healthcare Professional; Prescription Medication; Biological Product;
D O I：
10.2165/00128415-200812050-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 1
相关论文
共 50 条
  • [31] Drug use in pregnancy
    Leppée, Marcel
    Culig, Josip
    Polic-Vizintin, Marina
    Grgic, Matijana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S142 - S143
  • [32] Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition
    Price, Hayley R.
    Collier, Abby C.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (40) : 6098 - 6114
  • [33] FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone
    Cohen, Barbara R.
    Mahoney, Karen M.
    Baro, Elande
    Squire, Claudia
    Beck, Melissa
    Travis, Sara
    Pike-McCrudden, Amanda
    Izem, Rima
    Woodcock, Janet
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2129 - 2136
  • [34] FDA Regulation of Off-label Drug Promotion Under Attack
    Kesselheim, Aaron S.
    Mello, Michelle M.
    Avorn, Jerry
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (05): : 445 - 446
  • [35] FDA off-track on off-label drug promotion
    不详
    LANCET, 2007, 370 (9604): : 1976 - 1976
  • [36] Improved QSAR model for cholestasis built with FDA drug label data
    Girireddy, M.
    Saiakhov, R.
    Chakravarti, S.
    TOXICOLOGY LETTERS, 2021, 350 : S165 - S165
  • [37] Drug labeling: FDA requires new label for antibiotics to prevent overuse
    Tiwary, D
    JOURNAL OF LAW MEDICINE & ETHICS, 2003, 31 (03): : 458 - 460
  • [38] Suboptimum use of FDA drug advisory committees
    Tapley, Asa L.
    Lurie, Peter
    Wolfe, Sidney M.
    LANCET, 2006, 368 (9554): : 2210 - 2210
  • [39] AN FDA PERSPECTIVE ON DRUG-USE IN HORSES
    BEAULIEU, AJ
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1990, 196 (09) : 1388 - 1389
  • [40] Multiple drugHypotension, drug exposure during pregnancy, lack of efficacy and off-label use
    Reactions Weekly, 2024, 1992 (1) : 124 - 124
12345